Palms West beating: Judge denies bail, house arrest for patient arrested in attack on nurse
(This story was updated because because an earlier version included an inaccuracy.)
WEST PALM BEACH — A judge has ordered that the man accused of beating a nurse at HCA Florida Palms West Hospital and fracturing 'essentially every bone' in her face remain in jail without bail.
Stephen Scantlebury, 33, from Wellington, is facing a charge of attempted second-degree murder in the Feb. 18 attack on Leelamma Lal, a 67-year old nurse from Royal Palm Beach who remains in critical condition at St. Mary's Medical Center in West Palm Beach and may lose her eyesight.
The Palm Beach County Sheriff's Office also enhanced the charge to a hate crime saying Scantlebury had "made utterances" about the victim's gender, race or religion but did not specify which one. Lal is of Indian descent.
From the courts: Boca businessman who stole $1.45 million from 'friend' asks judge to spare him from prison
Scantlebury pleaded not guilty during a hearing Tuesday at the county jail, his first court appearance since the attack. His wife and children were also present in the courtroom, said Scott Simmons, his attorney with the Rossen Law Firm.
Circuit Judge Donald Hafele declined Simmons' request that Scantlebury be released on $125,000 bond, placed on house arrest and taken to a treatment facility.
The law firm issued a statement last week describing him as "a hardworking, loving husband, father and son" who is dealing with a form of mental illness it did not disclose. It cautioned that the public "has only heard one side of the story — the side presented by law enforcement" and said "the complete story" will come out in time.
After Hafele ordered Scantlebury remain in custody, Dr. Cindy Joseph, Lal's daughter and a neurologist with a practice in Melbourne, told the judge the family wouldn't feel safe if Scantlebury was allowed to go home and that he was a safety risk for the community.
Flanked by a dozen family members and a group of nurses, Joseph added her mother was intubated and still "fighting for her life."
"If he is released and disappears, justice for my mom will not be served,' Joseph said. 'Because of his actions, our lives will never be the same. We live in fear, constantly looking over our shoulders knowing that someone who's capable of such violence could walk free.'
Hafele on Tuesday directed the court to schedule a pretrial detention hearing for Scantlebury, where the issue of his bail and release could arise again. An initial case conference before Circuit Judge Caroline Shepherd is scheduled for April 10, online records show.
Boynton Beach homicide: PBSO says man accused of killing neighbor acted 'extremely weird' before attack
According to a sheriff's report, Lal was caring for Scantlebury, who had been evaluated at the hospital for mental-health issues under the state's Baker Act. Upon entering his room, Scantlebury jumped on top of Lal and hit her repeatedly with fists fracturing before fleeing the hospital.
Deputies arrested the 33-year-old Wellington resident as he ran along Southern Boulevard.
The beating has alarmed nurses and health care workers across Palm Beach County, many of whom rallied Sunday outside Palms West and at the Jerome Golden Center in West Palm Beach. A 2018 federal Bureau of Labor Statistics study found health care workers suffered nearly 75% of all cases of workforce violence.
A GoFundMe page launched by a friend of Lal's family to raise money for her care had raised nearly $135,000 as of Tuesday afternoon.
Sign up for our Post on Wellington weekly newsletter, delivered every Thursday!
Valentina Palm covers Royal Palm Beach, Wellington, Greenacres, Palm Springs and other western communities in Palm Beach County for The Palm Beach Post. Email her at vpalm@pbpost.com and follow her on X, the platform formerly known as Twitter, at @ValenPalmB. Support local journalism: Subscribe today.
This article originally appeared on Palm Beach Post: Palms West beating: Judge denies bail for patient in attack on nurse
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
2 hours ago
- Miami Herald
Texas Amber Alert for Missing Dallas Boy Canceled
Police said four-year-old Luciano Gallegos has been recovered after an Amber Alert was issued for his disappearance in Dallas, Texas, early on Tuesday morning. No further details were given. Newsweek has contacted the Dallas Police Department's public information office for more information. The original Amber Alert said Gallegos was taken by a 21-year-old man named Louis Ricker on Monday, June 9, and was last seen at 2900 Block of South Walton Walker Boulevard in Dallas, traveling southbound at around 11:30 p.m. in a White Mitsubishi Outlander. The Amber Alert system is used widely throughout the U.S., with 82 plans in place to help recover children after they have been determined missing, enabling some missing child reports to be resolved. The alerts can be issued on a state-wide or local scale and more than one child can be involved in the case. The system, which stands for America's Missing: Broadcast Emergency Response, dates back to 1996 when Dallas-Fort Worth broadcasters worked with the local police to develop a warning system to find abducted children, and later other states and communities soon set up their own plans. These alerts are broadcast through radio, TV, road signs, cellphones, and other data-enabled devices. The Amber Alert system is used in all 50 states, the District of Columbia, Indian country, Puerto Rico, the U.S. Virgin Islands, and 27 other countries. By the end of 2024, 1,268 children had been recovered due to the activation of an Amber Alert, according to the National Center for Missing & Exploited Children, which helps to distribute alerts to the public. This is a developing article. Updates to follow. Related Articles Amber Alert: Kidnapped Toddler, Mother 'Found Safe' in North CarolinaAbducted 8-Year-Old California Girl Found After Amber Alert IssuedAmber Alert Issued as 1-Year-Old Goes Missing in South DakotaAmber Alert Canceled for Missing 1-Year-Old From Washington State 2025 NEWSWEEK DIGITAL LLC.
Yahoo
3 hours ago
- Yahoo
Smuggler stopped with lizards, tarantulas, possums, authorities say
Indian customs officers made the latest "significant" seizure of endangered wildlife from a passenger arriving from Thailand, a government statement said: nearly 100 creatures including lizards, sunbirds and tree-climbing possums. Customs officers said the passenger, who was also carrying two tarantula spiders and tortoises, had "exhibited signs of nervousness" on arrival at India's financial capital Mumbai. The seizure comes after a passenger was stopped smuggling dozens of venomous vipers, also arriving from Thailand, earlier in June. They included 44 Indonesian pit vipers and were "concealed in checked-in baggage," Mumbai Customs said in a statement. The wildlife in the latest seizure included iguanas, as well as a kinkajou or honey bear -- a small raccoon-like animal from Mexico's rainforests -- along with six "sugar gliders" — a gliding possum found in Australia. Photographs released by the customs unit showed the six sugar gliders huddled together in a basket, as well as a box crammed with lizards. "In a significant operation, customs officers ... intercepted an Indian national ... leading to the seizure of multiple live and deceased wildlife species, some of which are protected under wildlife protection laws," the Ministry of Finance said in a statement late Monday. Disturbing smuggling trend Wildlife trade monitor TRAFFIC, which battles the smuggling of wild animals and plants, on Tuesday warned of a "very troubling" trend in trafficking driven by the exotic pet trade. More than 7,000 animals, dead and alive, have been seized along the Thailand-India air route in the last 3-and-a-half years, it said. Customs officers at Mumbai airport are more used to seizing smuggled gold, cash or cannabis -- but instances of wildlife seizure have seen a gradual rise recently. Customs officers seized dozens of snakes and several turtles from an Indian national flying from Thailand earlier in June. Among them were several spider-tailed horned vipers, a venomous species only described by scientists in 2006 and classified as "near-threatened" by the International Union for the Conservation of Nature (IUCN). TRAFFIC said its analysis showed that while most cases involve animals smuggled out of Thailand, more than 80 percent of interceptions happened in India. "The almost-weekly discoveries and diversity of wildlife en route to India is very troubling," said TRAFFIC's Southeast Asia director Kanitha Krishnasamy. Many of those captured were alive, which "shows that the clamor for exotic pets is driving the trade," she added. In February, customs officials at Mumbai airport also stopped a smuggler with five Siamang gibbons, a small ape native to the forests of Indonesia, Malaysia, and Thailand. Those small creatures, listed as endangered by the IUCN, were "ingeniously concealed" in a plastic crate placed inside the passenger's trolley bag, customs officers said. In November, authorities found a passenger carrying a wriggling live cargo of 12 turtles. Australian reporter covering Los Angeles protests shot with rubber bullet by police officer Kristi Noem says "we are not going to let a repeat of 2020 happen" amid L.A. crackdown LAPD chief speaks out about deployment of military forces to anti-ICE protests
Yahoo
4 hours ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need, and to capitalize on the immense commercial potential of our pipeline, we need to think prudently and practically about our manufacturing approach. In the short term, our manufacturing demands are almost 200 drug products per day, and this may increase as CAR-T cell therapies move closer to front line treatment. The only practical way for us to industrialize our production and produce a supply of drug product commensurate with total patient demand is to transition to G-Rex," said Dr. Lakshmikanth Gandikota, Head of R&D, MSAT Intellectual Property, and Translational Research, at Immuneel Therapeutics Limited. "We are extremely impressed by the speed, resourcefulness, creativity, discipline, and entrepreneurialism of the team at Immuneel and are happy to see that India, as a whole, is making significant strides toward CAR-T availability. It gives us a great sense of satisfaction to be in a position to help bring hope to cancer patients in India, one G-Rex at a time," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of Immuneel's G-Rex Grant, they will perform process development, qualification, and validation of a G-Rex based CAR-T cell therapy production approach to dramatically increase the throughput capacity of their state-of-the-art, 12,000 square foot GMP facility. Located in Bengaluru and opened in 2021, Immuneel's Integrated Cell Therapy Development and Manufacturing Facility was the first of its kind in India and is designed to bring breakthrough cell and gene therapies to millions of patients in India. Lastly, Immuneel's G-Rex Grant will support the requisite comparability studies necessary to support a post-CAR-T approval manufacturing change from their difficult to scale low throughput all-in-one manufacturing equipment to a much simpler high throughput G-Rex centric approach. The high popularity of ScaleReady's G-Rex Grant Program led ScaleReady to increase award funds from the original amount of $20M to a total of $30M directed towards saving recipients significant time and money by expediting the path to optimized cell and gene-modified cell therapy manufacturing. Two hundred grants have already been awarded with over 50 new applications in the queue. Each G-Rex Grant recipient can obtain up to $300,000 and gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact info@ About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized immunotherapies, for cancer patients in India. As a research-driven and fully integrated organization, Immuneel is dedicated to making next-generation cancer treatments accessible and affordable, with a strong focus on innovation and clinical impact. The company's mission is to democratize advanced therapies by developing and commercializing breakthrough solutions tailored to the needs of Indian patients. As part of its growing portfolio, Immuneel has licensed and commercialized Qartemi® (varnimcabtagene autoleucel), a CD19 CAR-T cell therapy approved by India's Central Drugs Standard Control Organization (CDSCO) for the treatment of adult B-cell non-Hodgkin lymphoma a novel therapy for blood cancer, further demonstrating its commitment to transforming cancer care in India. Immuneel has a robust pipeline of CAR-T therapies for various indications in Oncology and AutoImmune diseases For more information, please visit: View original content to download multimedia: SOURCE Bio-Techne Corporation
